Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression


ABSTRACT
BACKGROUND: The prevalence of depression is higher in individuals with autoimmune diseases, but the mechanisms underlying the observed comorbidities are unknown. Shared genetic etiology is a plausible explanation for the overlap, and in this study we tested whether genetic variation in the major histocompatibility complex (MHC), which is associated with risk for autoimmune diseases, is also associated with risk for depression.

METHODS: We fine-mapped the classical MHC (chr6: 29.6–33.1 Mb), imputing 216 human leukocyte antigen (HLA) alleles and 4 complement component 4 (C4) haplotypes in studies from the Psychiatric Genomics Consortium Major Depressive Disorder Working Group and the UK Biobank. The total sample size was 45,149 depression cases and 86,698 controls. We tested for association between depression status and imputed MHC variants, applying both a region-wide significance threshold ($3.9 \times 10^{-6}$) and a candidate threshold ($1.6 \times 10^{-4}$).

RESULTS: No HLA alleles or C4 haplotypes were associated with depression at the region-wide threshold. HLA-B*08:01 was associated with modest protection for depression at the candidate threshold for testing in HLA genes in the meta-analysis (odds ratio = 0.98, 95% confidence interval = 0.97–0.99).

CONCLUSIONS: We found no evidence that an increased risk for depression was conferred by HLA alleles, which play a major role in the genetic susceptibility to autoimmune diseases, or C4 haplotypes, which are strongly associated with schizophrenia. These results suggest that any HLA or C4 variants associated with depression either are rare or have very modest effect sizes.

Keywords: Autoimmune disorder, Complement, Genetic association, Human leukocyte antigen, Major depressive disorder, Major histocompatibility complex

https://doi.org/10.1016/j.biopsych.2019.06.031
Evidence of shared genetic influences in the major histocompatibility complex (MHC).

Epidemiological studies indicate that individuals with a history of autoimmune disease are at greater risk of developing mood disorders compared with individuals without a history of autoimmune disease (9–12). For example, a Danish Registry study (9) showed that the risk of a mood disorder increased following onset of any autoimmune disease (incident rate ratio = 1.45; 95% confidence interval [CI] = 1.39–1.52).

One interpretation is that the distress arising from autoimmune disorders is causal to the onset of a mood disorder. However, other evidence indicates that the relationship is bidirectional (13,14). For example, another Danish Registry study (13) showed that individuals with depression were at increased risk for developing any autoimmune disease (incident rate ratio = 1.25, 95% CI = 1.19–1.31) and that this increase remained relatively stable across the first decade after diagnosis of depression.

There are several plausible explanations for the observed overlap between depression and autoimmunity. Shared environmental influences may increase risk for both disorders—for example, stress is a risk factor for autoimmune disease (15)—and there is a phenotypic and genetic correlation between anxiety and depression (16). Another view is that shared genetic influences act on autoimmune disease and depression through common immune pathways. Efforts to identify shared genetic influences were undertaken in a recent genome-wide association study (GWAS) of depression, using linkage disequilibrium (LD) score regression to estimate genetic correlations between depression and autoimmune diseases (17).

There was no evidence for significant cross-trait correlations; the strongest correlation observed was between depression and inflammatory bowel disease (r_g = 0.07, p = 0.06). However, methods to detect genome-wide pleiotropy will not detect shared association at specific variants. Genetic variation in the MHC, which plays a crucial role in human immunity (18), should be thoroughly interrogated in depression.

The MHC is divided into 3 functionally distinct regions: class I and II regions contain highly polymorphic human leukocyte antigen (HLA) genes that are strongly associated with risk for autoimmune disease (19–21), and the class III region contains complement component 4 (C4) genes, which are strongly associated with risk for schizophrenia (22). Three recent GWASs indicated that genetic variation within the MHC is involved in risk for depression (17,23,24), with the strongest association located in the classical or extended class I region.

Highly polymorphic loci and long-range LD in the MHC complicate the interpretation of single nucleotide polymorphism (SNP) associations (17). However, imputed HLA alleles (25) and C4 haplotypes (22) can dissect SNP signal in the region with fine-mapping techniques. We used this approach to test whether genetic variation associated with autoimmune disease and schizophrenia is also associated with depression. Common SNPs in the MHC were tested to confirm that the pattern of association with depression was consistent with the pattern observed in previous GWASs and to provide a backbone of association across this region (17). We imputed HLA variants and common C4 haplotypes and tested whether these were associated with depression. We additionally extracted HLA alleles that increase risk of autoimmune diseases to test for association with depression. Finally, to explore the relationship between the association with HLA alleles and C4 haplotypes, we tested for association of depression with genetically predicted C4A brain expression and performed conditional analysis to assess evidence for association at HLA alleles and C4 haplotypes in strong LD.

To our knowledge, this is the first study to leverage impu-tation to interrogate the involvement of HLA alleles and C4 haplotypes in depression. Our efforts should lead to a better understanding of the role of these loci in depression and may provide insights into the mechanisms driving comorbid autoimmunity and depression.

METHODS AND MATERIALS

Participants

Participant data came from a subset of the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (PGC-MDD) (17) and from the UK Biobank (UKB) (26) to give a total of 131,847 individuals of European ancestry (55% female subjects, 45,149 depression cases, and 86,698 controls). Individual-level genotype and phenotype data were available for 26 PGC-MDD studies, totaling 39,145 individuals (54% female subjects, 15,805 cases, and 23,340 controls). Across the PGC-MDD studies, structured diagnostic interviews were conducted to identify case subjects with a lifetime diagnosis of MDD according to the DSM-IV (27), the ICD-9 (28), the ICD-10 (29), or the Composite International Diagnostic Interview Short Form (30). In most PGC-MDD studies, bipolar disorder, nonaffective psychosis, and substance use disorder were exclusion criteria in the cases, and controls were screened for absence of MDD and other psychiatric disorders. Ethical approvals were obtained by the principal investigators of each study, with all participants giving full informed consent.

The UKB is a prospective cohort study that has collected genotype and phenotype data for more than 500,000 individuals across the UK, between 40 and 69 years of age at recruitment (26). A total of 157,366 UKB participants completed an online mental health questionnaire, which assesses lifetime depressive disorder (31). Using the recommended mental health questionnaire scoring protocol (31), we identified 29,344 individuals with lifetime depressive disorder and 63,358 controls. Cases were excluded if they endorsed diagnosis of psychosis or bipolar disorder. Controls were excluded if they endorsed diagnosis of any psychiatric disorder in the mental health questionnaire, or self-reported depression or use of antidepressant medication at baseline and follow-up interviews, or had a mood disorder according to hospital episode statistics, or met the criteria for a mood disorder according to Smith et al. (32). Further details of the PGC-MDD and UKB samples are in Table S1 in Supplement 2.

Genotyping and Quality Control

Quality control (QC) of genotype data in the 26 PGC-MDD studies was performed by the PGC Statistical Analysis Group using the ricopili pipeline (17) with the following thresholds: SNP missingness (before individual QC) < 0.05, individual missingness < 0.02, SNP missingness (after individual QC) < 0.02, deviation from heterozygosity |Fhet| < 0.20, Hardy-
Weinberg equilibrium $p$ value $> 10^{-10}$ (cases) and $p$ value $> 10^{-6}$ (controls). After imputation with the 1000 Genomes reference panel (17), SNPs with INFO score $> 0.8$ and minor allele frequency (MAF) $> 0.05$ were retained for relatedness testing and principal component analysis. One individual from each pair with relatedness $> 0.2$ was removed, and only individuals of European ancestry were retained.

Using genotype data that had undergone preliminary QC by the UKB (26), we created an inclusion list of individuals of European ancestry using 4-means clustering on the first 2 principal components provided by the UKB. Using relatedness kinship (KING) estimates provided by the UKB, we removed 1 individual from each pair up to 3rd-degree relationships (KING $r^2 > 0.044$) (33). In the remaining data, we applied QC with the following thresholds: SNP missingness (before individual QC) < 0.02, individual missingness < 0.02, SNP missingness (after individual QC) < 0.02, MAF > 0.01, Hardy-Weinberg equilibrium value $2$ of the 26 PGC-MDD analyses in each study, we used the Genetic Type I error calculator (GEC) (42), an online resource that calculates the number of effective tests by dividing the total number of tests by the number of independent tests.

<table>
<thead>
<tr>
<th>Gene</th>
<th>PGC-MDD</th>
<th>UKB</th>
<th>Variants in Both PGC-MDD and UKB</th>
<th>Variants in Either PGC-MDD or UKB</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-A</td>
<td>31</td>
<td>13</td>
<td>13</td>
<td>31</td>
</tr>
<tr>
<td>HLA-B</td>
<td>48</td>
<td>18</td>
<td>18</td>
<td>48</td>
</tr>
<tr>
<td>HLA-C</td>
<td>30</td>
<td>14</td>
<td>14</td>
<td>30</td>
</tr>
<tr>
<td>HLA-DPA</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>HLA-DRB</td>
<td>25</td>
<td>11</td>
<td>11</td>
<td>25</td>
</tr>
<tr>
<td>HLA-DQA</td>
<td>12</td>
<td>7</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>HLA-DQB</td>
<td>19</td>
<td>12</td>
<td>12</td>
<td>19</td>
</tr>
<tr>
<td>HLA-DRB</td>
<td>37</td>
<td>24</td>
<td>15</td>
<td>46</td>
</tr>
<tr>
<td>Total HLA Alleles</td>
<td>207</td>
<td>102</td>
<td>93</td>
<td>216</td>
</tr>
<tr>
<td>C4 Haplotypes</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>SNPs</td>
<td>49,611</td>
<td>47,799</td>
<td>40,561</td>
<td>56,779</td>
</tr>
</tbody>
</table>

C4B genes in short and long form. Four C4 haplotypes with frequency $>0.01$ were retained: AL-AL, AL-BL, AL-BS, and BS (where A and B correspond to 2 isotypes of the C4 gene and L and S correspond to the long and short forms). Of the common C4 haplotypes, 3 (AL-AL, AL-BL, and AL-BS) segregate on 2, 3, and 5 different SNP haplotypes, respectively. Association results for these C4 haplotypes were calculated by meta-analyzing across SNP haplotypes corresponding to each C4 structure.

**Statistical Analyses**

In the PGC-MDD group, we tested each HLA allele and C4 haplotype for association with MDD case-control status using an additive logistic regression model applied to dosage data. We included 6 principal components to control for population structure. We extracted association results for SNPs in the classical MHC from PGC-MDD analyses in each study, applying further QC such that only variants with a MAF $> 0.01$ and an INFO score $\geq 0.6$ were retained. Post-QC variants were meta-analyzed across the 26 PGC-MDD studies using an inverse-variance weighted approach.

In the UKB sample, we tested each HLA allele, C4 haplotype, and imputed SNP for association with depression case-control status using an additive linear regression model applied to dosage data. We regressed 6 principal components (calculated by the UKB), batch, and center on the depression phenotype using logistic regression in R 3.4.1 (41), and used the residuals as the outcome variable in subsequent linear regression. We filtered for variants with a MAF $> 0.01$ and an INFO score $\geq 0.6$ before meta-analyzing across the PGC-MDD and UKB results. Analyses were performed using PLINK (version 1.9 and version 2.0) (37). Further details of QC, imputation, and analysis are given in the Supplement.

To calculate the MHC region-wide significance threshold, we used the Genetic Type I error calculator (GEC) (42), an online resource that calculates the number of effective tests by...
HLA Alleles, C4 Haplotypes, and Depression Risk

estimating LD between variants and applying a Bonferroni correction. We calculated a conservative region-wide significance threshold \((3.9 \times 10^{-6})\), controlling for all imputed SNPs in the classical MHC, and a candidate significance threshold \((1.6 \times 10^{-4})\), controlling only for HLA intragenic SNPs in the classical MHC. A summary of all analyses performed is given in Table S2 in Supplement 2.

We used the Genetic Power Calculator (43) to estimate power at the minimum and maximum INFO score thresholds. At an INFO score of 1.0, the effective sample size was 45,149 cases and 86,698 controls. For an HLA allele of frequency 0.05 (the median in our study), we had 80% power to detect an odds ratio (OR) >1.09, at a region-wide significance level of \(\alpha = 3.9 \times 10^{-6}\). At an INFO score of 0.6, the effective sample size was 27,089 cases and 52,018 controls. For an HLA allele of frequency 0.05, we had 80% power to detect an OR >1.12, at a region-wide significance level of \(\alpha = 3.9 \times 10^{-6}\).

We compared the imputation accuracy and frequency of HLA alleles and C4 haplotypes in the PGC-MDD and UKB samples for variants present in both samples. The average imputation INFO score and frequency were calculated by weighting variant INFO scores and frequencies by the effective sample size in each PGC-MDD study.

The genetic correlation between the PGC-MDD and UKB samples was calculated using the LD Score software (version 1.0.0) (44) using GWAS summary statistics for these data sets that had been previously calculated (17,45). The local heritability of depression in the MHC was calculated using the HESS software (46), which partitions heritability into LD blocks across the genome. Using summary statistics from the PGC-MDD GWAS of depression (17) (excluding 23andMe data), we calculated the genome-wide heritability of depression and extracted the heritability estimates for the 5 LD partitions that constitute the extended MHC.

Drawing on evidence from epidemiological studies (9,13), we identified autoimmune diseases with evidence for a bidirectional relationship with depression. We identified individuals affected by these autoimmune diseases in the UKB using hospital episode statistics and self-reported conditions. HLA risk alleles for these autoimmune diseases were identified by conducting a PubMed search using the terms “HLA” and relevant disease name. HLA alleles with evidence for independent association \((p < 3.9 \times 10^{-5})\) in European populations were retained. We evaluated evidence for involvement of these HLA alleles in depression, selecting those with MAF >0.05 in our study. We used the GEC (42) to determine the effective number of tests across 14 HLA alleles, and we obtained the \(p\) value threshold of \(0.05/11.75 = .004\).

To dissect the combined contribution of HLA alleles and C4 haplotypes to risk of depression, we performed conditional analysis of HLA alleles associated with depression and C4 haplotypes in strong LD with these variants. The LD \((r^2)\) between each common C4 haplotype (AL-AL, AL-BL, AL-BS, and BS) and all imputed HLA alleles in the UKB data set was calculated using PLINK (37).

Genetically predicted C4A brain expression was calculated for each individual. We leveraged work from Sekar et al. (22), who estimated the contribution of each C4 structure to C4A brain expression in postmortem brain tissue. From this model, we estimated C4A brain expression corresponding to each C4 haplotype (Table S3 in Supplement 2) and calculated individual-level C4A brain expression by multiplying the dosage for each C4 haplotype by the corresponding value for C4A brain expression. We then tested genetically predicted C4A brain expression for association with depression in the PGC-MDD and UKB samples.

RESULTS

In total, 207 HLA alleles were imputed in at least 2 PGC-MDD studies, and 102 HLA alleles were imputed in the UKB sample, of which 93 were shared across data sets (Table 1). Variants imputed in either data set were included in the final meta-analysis (minimum effective sample size was 669 for HLA-B-3906 in the PGC-MDD). Four C4 haplotypes (AL-AL, AL-BL, AL-BS, BS) were imputed in all data sets.

There was strong consistency between the frequency and INFO scores of HLA alleles and C4 haplotypes imputed in both the PGC-MDD and UKB samples (correlation \(r = .99\) for frequency and \(r = .86\) for INFO score) (Figures S2 and S3 in Supplement 1). The INFO score for imputed alleles was higher in the UKB than in the PGC-MDD studies (UKB mean = 0.98, PGC-MDD mean = 0.96), possibly because of the larger HLA reference panel or greater efficiency of the imputation algorithm used.

The genetic correlation between the PGC-MDD and the UKB samples was 0.79 (SE = 0.088). The genome-wide heritability estimate of MDD on the liability scale was 0.09 (SE = 0.01). The estimate of local heritability of MDD across the 5 LD partitions within the MHC was not significant (Figure S4 in Supplement 1, Table S4 in Supplement 1).

Testing for association with depression in the PGC-MDD sample, no HLA allele, C4 haplotype, or SNP surpassed region-wide significance (Figure 1A). In the UKB, no HLA allele or C4 haplotype surpassed region-wide significance (Figure 1B). The allele with strongest evidence for association was HLA-B*08:01 (\(p = 4 \times 10^{-4}\), OR = 0.98, 95% CI = 0.97–0.99). Among SNPs, 70 met region-wide significance (Table S5 in Supplement 2). The variant with the lowest \(p\) value was a SNP in the classical class I region: rs1264373 (\(p = 10^{-8}\), OR = 0.97, 95% CI = 0.96–0.98). All variants surpassing region-wide significance were in LD with rs1264373 (0.66 < \(r^2 < 1.00\)), and rs1264373 was also in LD with the most significant MHC SNP in the PGC-MDD GWAS (17) (rs115507122, \(r^2 = .63\)).

Figure 1. Region-wide Manhattan plots for single nucleotide polymorphisms (SNPs) (gray), human leukocyte antigen (HLA) alleles (HLA-A, HLA-B, and HLA-C [red] and HLA-DPA, HLA-DPB, HLA-DQA, HLA-DQB, and HLA-DRB [green]), and complement component 4 (C4) haplotypes (C4-AL-AL, C4-AL-BS, C4-BS, and C4-AL-BL [blue], where A and B represent the isotype of the C4 gene, L indicates the long form, and S indicates the short form) in (A) Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (PGC-MDD) studies, (B) UK Biobank sample, and (C) meta-analysis of PGC-MDD studies and UK Biobank sample. chr, chromosome; Indels, insertions and deletions; MHC, major histocompatibility complex.
In the meta-analysis, no HLA allele or C4 haplotype met region-wide significance; HLA-B*0801 met the candidate threshold \( (p = 1.26 \times 10^{-4}, \text{OR} = 0.98, 95\% \text{ CI} = 0.97–0.99) \) (Figure 1C). A total of 143 SNPs reached region-wide significance (Table S6 in Supplement 2). The variant with the lowest \( p \) value was a SNP in the classical class I region: rs9262120 \( (p = 8.74 \times 10^{-6}, \text{OR} = 1.03, 95\% \text{ CI} = 1.02–1.05) \). This SNP was in LD with the other 142 significant variants \( (0.44 < r^2 < 1.00) \), and with the most significant SNP within the MHC in the PGC-MDD GWAS \( (r^2 = 0.66) \). Low heterogeneity was observed between most variants in the UKB and PGC-MDD meta-analysis; 72% of variants had an \( r^2 \) value below 0.25 (Figures S5 and S6 in Supplement 1).

We identified 6 autoimmune diseases with evidence for a bidirectional relationship with depression: Crohn’s disease, multiple sclerosis, primary adrenocortical insufficiency, psoriasis vulgaris, systemic lupus erythematosus (SLE), and type 1 diabetes mellitus \( (9,13) \). We identified 14 HLA alleles associated with risk for these autoimmune diseases \( (p < 3.9 \times 10^{-6}) \) in European populations \( (47–58) \), with MAF > 0.05 in our study. Three HLA alleles had evidence for association with depression after correcting for multiple testing \( (p < .004) \): HLA-B*08:01 and HLA-DQB1*02:01 (SLE) and HLA-DRB1*03:01 (multiple sclerosis, primary adrenocortical insufficiency, SLE) (Table 2). These alleles were in strong LD with the C4-BS haplotype in the UKB sample; the \( r^2 \) values with HLA-B*08:01, HLA-DRB1*03:01, and HLA-DQB1*02:01 were 0.70, and 0.68, respectively (Figure S7 in Supplement 1 and Tables S7 and S8 in Supplement 1). Evidence for association with the HLA alleles attenuated after conditioning on C4-BS \( (p = .008, \rho = 2, \text{and} \rho = 3, \text{respectively}) \), but the HLA allele showed stronger association than the C4-BS haplotype did (Tables S9–11 in Supplement 1).

Genetically predicted C4A brain expression was not significantly associated with depression status in the PGC-MDD sample \( (p = .066, \text{OR} = 1.06, 95\% \text{ CI} = 1.00–1.13) \), the UKB sample \( (p = .333, \text{OR} = 1.01, 95\% \text{ CI} = 0.99–1.03) \), or the meta-analysis \( (p = .150, \text{OR} = 1.01, 95\% \text{ CI} = 0.99–1.03) \) (Figure 2 and Table S12 in Supplement 2).

**DISCUSSION**

To further understand the mechanisms driving comorbid autoimmunity and depression, we investigated evidence for shared genetic influences in the MHC, a region harboring genetic risk for autoimmune diseases and psychiatric disorders. Our primary aim was to test HLA alleles and C4 haplotypes for association with depression. Under a conservative region-wide significance threshold testing for all variants in the MHC, we found no evidence that HLA alleles, which play a major role in susceptibility to autoimmune diseases, or C4 haplotypes, which are strongly associated with risk for schizophrenia, also confer risk for depression. However, under a candidate threshold, correcting for SNPs within HLA genes, HLA-B*0801 had significant

### Table 2. HLA Alleles Associated With Risk for 6 Autoimmune Diseases

<table>
<thead>
<tr>
<th>Trait (References) [Prevalence in the UKB Sample in Depression Cases, Controls]</th>
<th>HLA Allele</th>
<th>Effect in Autoimmune Disease</th>
<th>PGC-MDD</th>
<th>UKB</th>
<th>Meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crohn’s Disease ( (47,48) ) [0.46%, 0.39%]</td>
<td>HLA-A*03:01</td>
<td>1.10</td>
<td>1.07–1.15</td>
<td>0.15</td>
<td>0.96</td>
</tr>
<tr>
<td></td>
<td>HLA-C*06:02</td>
<td>1.17</td>
<td>1.13–1.23</td>
<td>0.09</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>HLA-DRB1*07:01</td>
<td>1.14</td>
<td>1.10–1.18</td>
<td>0.13</td>
<td>1.01</td>
</tr>
<tr>
<td></td>
<td>HLA-DRB1*13:02</td>
<td>1.20</td>
<td>1.19–1.28</td>
<td>0.05</td>
<td>0.97</td>
</tr>
<tr>
<td>Multiple Sclerosis ( (49,50) ) [0.48%, 0.27%]</td>
<td>HLA-DQB1*03:02</td>
<td>1.30</td>
<td>1.29–1.37</td>
<td>0.11</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>HLA-DRB1*03:01</td>
<td>1.16</td>
<td>1.10–1.22</td>
<td>0.13</td>
<td>0.95</td>
</tr>
<tr>
<td></td>
<td>HLA-DRB1*15:01</td>
<td>3.92</td>
<td>3.74–4.12</td>
<td>0.14</td>
<td>0.98</td>
</tr>
<tr>
<td>Primary Adrenocortical Insufficiency (Addison’s Disease) ( (51,52) )</td>
<td>HLA-DRB1*03:01</td>
<td>2.93</td>
<td>2.12–4.04</td>
<td>0.13</td>
<td>0.95</td>
</tr>
<tr>
<td>Psoriasis Vulgaris ( (53,54) ) [1.56%, 1.21%]</td>
<td>HLA-A*02:01</td>
<td>1.20</td>
<td>1.08–1.33</td>
<td>0.28</td>
<td>1.01</td>
</tr>
<tr>
<td></td>
<td>HLA-C*06:02</td>
<td>3.57</td>
<td>3.12–4.08</td>
<td>0.09</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>HLA-DQA1*02:01</td>
<td>1.99</td>
<td>1.74–2.27</td>
<td>0.13</td>
<td>1.01</td>
</tr>
<tr>
<td>Systemic Lupus Erythematosus ( (55,56) ) [0.21%, 0.11%]</td>
<td>HLA-B*08:01</td>
<td>1.84</td>
<td>1.70–1.99</td>
<td>0.12</td>
<td>0.96</td>
</tr>
<tr>
<td></td>
<td>HLA-DQA1*01:02</td>
<td>1.31</td>
<td>1.22–1.40</td>
<td>0.20</td>
<td>0.97</td>
</tr>
<tr>
<td></td>
<td>HLA-DQB1*02:01</td>
<td>1.84</td>
<td>1.71–1.99</td>
<td>0.13</td>
<td>0.95</td>
</tr>
<tr>
<td></td>
<td>HLA-DRB1*03:01</td>
<td>1.87</td>
<td>1.73–2.02</td>
<td>0.13</td>
<td>0.95</td>
</tr>
<tr>
<td>Type 1 Diabetes Mellitus ( (57,58) ) [0.48%, 0.35%]</td>
<td>HLA-A*24:02</td>
<td>1.32</td>
<td>NA</td>
<td>0.08</td>
<td>0.97</td>
</tr>
<tr>
<td></td>
<td>HLA-DPB1*01:01</td>
<td>1.27</td>
<td>NA</td>
<td>0.05</td>
<td>0.92</td>
</tr>
</tbody>
</table>

The prevalence of each autoimmune disease, with the exception of primary adrenocortical insufficiency, which is very rare, within depression cases and controls in the UK Biobank (UKB) sample is shown in the first column. Columns 2–4 show the human leukocyte antigen (HLA) allele association with each autoimmune disease as estimated in the primary studies cited. Remaining columns show the HLA allele association with depression in the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium (PGC-MDD), UKB, and meta-analysis. CI, confidence interval; Frq, allele frequency; NA, not available in primary study; OR, odds ratio. *p values met correction for multiple testing.
evidence for association with depression status. Conditioning on the C4-BS haplotype resulted in moderate attenuation of signal from HLA-B*0801, indicating independence from C4 haplotypes.

The local heritability estimate of depression in the MHC region was not significant, which is unsurprising given the narrow region considered and the modest SNP heritability for depression across the genome ($h^2 = 0.09$).

We further explored common HLA alleles associated with autoimmune diseases that have evidence of a bidirectional relationship with depression. The allele with strongest evidence for association with depression was HLA-B*08:01, followed by HLA-DQB1*02:01 and HLA-DRB1*03:01. Previous studies have shown that all 3 HLA alleles increase risk for SLE (55,56) and that HLA-DRB1*03:01 also increases risk for multiple sclerosis (49,50) and primary adrenocortical insufficiency (51,52). In contrast, our findings indicate that HLA-B*08:01, HLA-DQB1*02:01, and HLA-DRB1*03:01 have modest protective effects in depression, indicating that these alleles do not harbor shared risk for autoimmune disease and depression.

Imputation of C4 haplotypes identified 4 common haplotypes, none of which was associated with risk for depression in the PGC-MDD studies, UKB sample, or meta-analysis. These results are in stark contrast to those for schizophrenia, where association with C4 haplotypes accounts for most of the observed SNP association in the HLA region. Our results suggest that C4 does not contribute to the common genetic susceptibility between depression and schizophrenia (genetic correlation $r_g = .34$).

At the level of region-wide significance, we detected 70 SNPs associated with depression in the UKB sample and 143 in the meta-analysis. In each case, the top SNP was in moderate to strong LD. This was not unexpected given that our study is a subset of the studies included in the PGC-MDD meta-analysis (17).

The true identity of causal variants within the MHC remains unresolved, and fine-mapping within the MHC is challenging because of the high density of genetic variation and strong LD. Our results strongly suggest that the association signal observed in the MHC in depression (17,23) does not arise from HLA alleles or C4 haplotypes. These results suggest that any associated variants either are rare or have very modest effect sizes. We note that Howard et al. (23) increased power by leveraging a broader phenotyping approach. It is interesting to speculate that the broader depression phenotype captures individuals distressed by physical disease. This interpretation would go some way to explaining signal in the MHC, for which there is evidence for association with more diseases than any other region of the genome (18). However, a more parsimonious explanation could be that MHC signal in depression maps to SNPs or to other genetic loci not imputed in this study. This possibility is highly plausible in light of the fact that the MHC contains more genes than any other region in the human genome (18). Under this scenario, large sample sizes and sequencing may be required to dissect SNP signal within the MHC.

Our findings do not support a role for HLA alleles within the MHC in risk for depression, and cross-trait correlations performed by the PGC-MDD (17) do not support the theory that shared genetic risk for depression and autoimmune diseases is situated outside the MHC. In other efforts to detect genome-wide pleiotropy, Euesden et al. (14) found no evidence that polygenic risk scores for rheumatoid arthritis predicted depression status in an independent sample, nor did polygenic risk scores for depression predict autoimmune disease status.

One possibility is that there is a subgroup of individuals enriched for depression and autoimmune risk alleles. Under this scenario, there may be insufficient power to detect the relationship. Identifying, for example, a subgroup of individuals with depression, who are also enriched for autoimmune risk alleles, would go some way to explaining the observed comorbidity between these traits. Furthermore, identifying a subtype of depression, e.g., an “immune-related” depression group, would help to dissect heterogeneity in the depression phenotype.

In summary, this study is the first to interrogate the involvement of HLA alleles and C4 haplotypes in depression risk, and we find no evidence that either type of genetic variant plays a major role in susceptibility for depression. In contrast, the 3 HLA alleles that showed nominal significance in our study conferred modest protective effects for depression. Furthermore, the strong association with C4 alleles that is seen in cases of schizophrenia is absent in cases of depression. Large sample sizes and regional sequence data may be required to dissect SNP signal within the MHC.

**ACKNOWLEDGMENTS AND DISCLOSURES**

This work was supported by the UK Medical Research Council (Grant No. MR/N015746/1 Grant No. MR/N015746/1, Ph.D. studentship [to KPG]) and partially funded by the National Institute for Health Research (NIHR).
Biomedical Research Centre at South London and Maudsley National Health Service (NHS) Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

We thank participants and scientists involved in making the UK Biobank resource available (http://www.ukbiobank.ac.uk/). UK Biobank data used in this study were obtained under approved application 18177, which was supported by funding from the Medical Research Council (Grant No. MR/N015746/1).

We are deeply indebted to the investigators who comprise the PGC and to the hundreds of thousands of participants who have shared their life experiences with PGC investigators. The PGC has received major funding from the United States National Institute of Mental Health (Grant No. U01 MH109528-03 [principal investigator, P.F. Sullivan]), the United States National Institute of Drug Abuse (Grant No. U01 MH1095320 [principal investigator A. Agravall]), the Netherlands Scientific Organization (Grant No. 480-05-003 [principal investigator, D. Posthuma]), and the Dutch Brain Foundation and the Vrije Universiteit Amsterdam (principal investigator, D. Posthuma).

We thank contributors to the primary studies constituting the PGC-MDD sample in this article.

**BOMA**: Funding support was provided by Deutsche Forschungsgemeinschaft, Germany (Grant Nos. RI 908/11-1, N0246/10-1 and Excellence Cluster ImmunoSensation [principal investigators, M. Rietschel and M.M. Nöthen]), the German Federal Ministry for Education and Research (BMBF) IntegraMent, Germany (Grant Nos. 01ZX1314A/01ZX1614A and 01ZX1314G/01ZX1614G [principal investigators, M.M. Nöthen, M. Rietschel, and S. Cichon]), and BMBF NGFNPuls MooDS, Germany (Grant Nos. 01GS08144 and 01GS08147 [principal investigators, M.M. Nöthen, M. Rietschel, and S. Cichon]).

**CoFaMS – Adelaide**: Funding support was provided by the National Health and Medical Research Council, Australia (Grant No. APP1006052 [principal investigator, B.T. Baune]).

**Danish Radiant**: Funding support was provided by Højteknologifonden, Denmark (Grant No. 0001-2009-2 [principal investigators, T. Werge (controls) and O. Mors (cases)]) and Lundbeck Foundation, Denmark (Grant No. R24-A3242 [principal investigators, T. Werge (controls) and O. Mors (cases)]).

**EDINBURGH**: Genotyping was conducted at the Genetics Core Laboratory at the Clinical Research Facility (University of Edinburgh). Funding support was provided by Wellcome Trust, UK (Grant No. 104036/Z/14/Z [principal investigator, A.M. McIntosh]).

**GenPod/Newmeds**: Funding support was provided by the Medical Research Council, UK (Grant No. G0200243 [principal investigators, G. Lewis and M. O’Donovan]), EU 6th framework, UK (Grant No. LSHB-CT-2003-503428 [principal investigator, R. Uher]), and EU Innovative Medicines Initiative Joint Undertaking, UK (Grant No. 15008 [principal investigator, G. Lewis]).

**GSK-MUNICH**: We thank all participants in the GSK-Munich study. We thank numerous people at GSK and Max Planck Institute, BKH Augsburg, and Klinikum Ingolstadt in Germany who contributed to this project.

**Harvard i2b2**: Funding support was provided by the National Institute of Mental Health (NIMH) (Grant Nos. R01 MH088542 and R01 MH086026 [principal investigators, J.W. Smoller and R.H. Perlis]).

**MARS**: This work was funded by the Max Planck Society, the Max Planck Excellence Foundation, the BMBF in the National Genome Research Network framework (NGFN2 and NGFN-Plus) (Grant No. FKZ 01GS0481), and by the BMBF Program (Grant No. FKZ 01ES0811). We acknowledge all study participants. We thank numerous people at Max Planck Institute, and all study sites in Germany and Switzerland who contributed to this project. Controls were from the Dortmund Health Study, which was supported by unrestricted grants to the University of Münster from Almirall, AstraZeneca, Berlin Chemie, Boehringer, Boots Health Care, Glaxo-Smith-Kline, Janssen Cilag, McNeil Pharma, MSD Sharp and Dohme, and Pfizer. Blood collection was funded by the Institute of Epidemiology and Social Medicine, University of Munich. Genotyping was supported by the Genomics-Netzwerk (Grant No. E-2005-1121 [principal investigator, U. de Faire]).

**NESDA**: The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organization for Health Research and Development (ZonMw) (Grant No. 10-000-1002) and financial contributions by participating universities and mental health care organizations (Vrije Universiteit Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, and Rob Giel Onderzoekcentrum). Genotyping was supported by the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL) and National Institutes of Health (Genetic Association Information Network [GAIN] of the Foundation for the National Institutes of Health, Grand Opportunity Grant Nos. 1RC2 MH089951 and 1RC2 MH089995 [principal investigator, B.J.W. Penninx]).

**NTR**: is supported by the Netherlands Organization for Scientific Research (NOW) (Grant No. 480-15-001/674).

**BBMRI-NL**: Funding support was provided by Biobanking and Biomolecular Resources Research Infrastructure (Grant Nos. 184.021.007 and BBMRI-NL2.0.184.033.111). Genotyping was supported by BBMRI-NL, the Avera Institute, Sioux Falls, SD, and National Institutes of Health (Genetic Association Information Network [GAIN] of the Foundation for the National Institutes of Health, Grand Opportunity Grant Nos. 1RC2 MH089951 and 1RC2 MH089995 [principal investigator, D. Boomsma]).

**PsychOlaUs**: Funding support was provided by the Swiss National Science Foundation, Switzerland (Grant Nos. 3200B0-105993, 3200B0-118308, 33CSCCO-122661, 33CS30-139468, and 33CS30-148401 [principal investigator, M. Preissig]). PsychOlaUs/CoLaus received additional support from research grants from GlaxoSmithKline and the Faculty of Biology and Medicine of Lausanne.

**QIMR**: We thank the twins and their families for their willing participation in our studies. Funding support was provided by the National Health and Medical Research Council, Australia (Grant Nos. 941177, 971232, 3399450, and 443011 [principal investigator, N.G. Martin]) and National Institute on Alcohol Abuse and Alcoholism (Grant Nos. AA07535, AA07728, and AA10249 [principal investigator, A.C. Heath]).

**RADIANT**: This report represents independent research funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust, and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Funding support was provided by the Medical Research Council, UK (Grant Nos. G0701420 and G0901245 [principal investigators, C. Lewis and G. Brenni]) and NIMH, UK (Grant No. U01 MH109528 [principal investigator, G. Brenni]).

**Rotterdam Study**: Funding support was provided by the Netherlands Organization of Scientific Research (NWO) Investments (Grant No. 175.010.2005.011, 911-03-012 [principal investigator, A.G. Utterlinden]). The Rotterdam Study is also funded by Erasmus Medical Center and Erasmus University.

**SHIP-LEGEND/TREND**: SHIP is part of the Community Medicine Research net of the University of Greifswald, which is funded by the Federal Ministry of Education and Research (Grant Nos. 01ZZ9003, 01ZZ90103, and 01ZZ90043), the Ministry of Cultural Affairs, and the Social Ministry of the Federal State of Mecklenburg-West Pomerania. Genotyping in SHIP was funded by Siemens Healthcare and the Federal State of Mecklenburg-West Pomerania. The SHIP-LEGEND/TREND Study is also funded by the German Research Foundation (Grant No. DFG: GR 1912/5-1 [principal investigator, H.J. Graben]). Genotyping in SHIP-TREND-0 was supported by the Federal Ministry of Education and Research (Grant No. 03ZIK012).

**STAR-D**: The authors appreciate the efforts of the STAR-D investigator team for acquiring, compiling, and sharing the STAR-D clinical data set. Funding support was provided by NIMH (Grant No. R01 MH-072802 [principal investigator, S.P. Hamilton]).

**TwinGene**: Thanks the Karolinska Institutet for infrastructural support of the Swedish Twin Registry. Funding support was provided by GenomeEUtwins, EU (Grant Nos. EU/QLRT-2001-01254 and QLCT-2002-01254 [principal investigator, N. Pedersen]), the Heart and Lung foundation, Sweden (Grant No. 20070481 [principal investigator, P. Magnusson]), SSF, Sweden and Vetenskapsrådet, Sweden (Grant No. M-2005-1112 [principal investigator, U. de Faire]).

**Low-CASE**: Funding support was provided by the Genomics-Wide Association of Schizophrenia Study was provided by NIMH (Grant Nos. R01 MH67257, R01 MH59588, R01 MH59571, R01 MH59565, R01 MH59587, R01 MH60870, R01 MH59566, R01 MH59586, R01 MH61675, R01 MH60879, R01 MH61800.
HLA Alleles, C4 Haplotypes, and Depression Risk

U01 MH46276, U01 MH46289 U01 MH46318, U01 MH79469, and U01 MH79470, and the genotyping of samples was provided through GAIn. The data sets used for the analyses described in this manuscript were obtained from the database of Genotypes and Phenotypes (dbGaP) found at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000021.v3.p2. Samples and associated phenotype data for the Genome-Wide Association of Schizophrenia Study were provided by the Molecular Genetics of Schizophrenia Collaboration (principal investigator, Pablo V. Gejman, Evanston Northwestern Healthcare (ENH) and Northwestern University, Evanston, IL). Statistical analyses were performed on the NL Genetic Cluster computer (http://www.geneticcluster.org/) hosted by SURFsara, and the King’s Health Partners High Performance Compute Cluster funded with capital equipment grants from the Guy’s and St Thomas’ Charity (Grant No. TR130505) and Maudsley Charity (Grant No. 980).

JE is an employee of GlaxoSmithKline Pharmaceuticals. PFS is on the scientific advisory board for Pfizer and the advisory committee for Lundbeck. All other authors report no biomedical financial interests or potential conflicts of interest.

Due to the highly sensitive nature of genetic information used in this study, supporting data cannot be made openly available. Researchers may apply to the Psychiatric Genomics Consortium (https://www.med.unc.edu/pgc/shared-methods/) and/or UK Biobank (https://www.ukbiobank.ac.uk/) to gain access to the supporting data.

ARTICLE INFORMATION

From the Social Genetic and Developmental Psychiatry Centre (KPG, JRIC, JE, SWC, KLP, GB, PM, PFO, CML), Institute of Psychiatry, Psychology and Neuroscience; National Institute for Health Research Biomedical Research Centre South London and Maudsley National Health Service Trust (JRIC, GB); and Department of Medical and Molecular Genetics (KBH, CML), King’s College London; Division of Psychiatry (GL), University College London, London; Division of Psychiatry (DHRB, AMM); and Centre for Cognitive Ageing and Cognitive Epidemiology (AMM), University of Edinburgh, Edinburgh; Medical Research Council Centre for Neurogenetic Psychiatry and Genomics (IJ), Cardiff University, Cardiff; Department of Psychological Medicine (LAJ), University of Worcester, Worcester; University of Liverpool (BM-M), Liverpool, United Kingdom; Genetics and Genomic Sciences (SWC, PFO), Icahn School of Medicine, Mount Sinai; Division of Epidemiology (MMW), New York State Psychiatric Institute; Department of Psychiatry (MMW), Columbia University College of Physicians and Surgeons, New York, New York; Department of Psychiatry and Behavioral Sciences (EBB), Emory University School of Medicine, Emory University, Atlanta, Georgia; Department of Psychiatry (ECD, JWS); Psychiatric and Neurodevelopmental Genomics Unit (ECM, ECD, JWS); and Analytic and Translational Genetics Unit (SR), Broad Institute, Cambridge, MA, USA (principal investigator, SamuelAmong others, researchers may apply to the Psychiatric Genomics Consortium (https://www.med.unc.edu/pgc/shared-methods/) and/or UK Biobank (https://www.ukbiobank.ac.uk/) to gain access to the supporting data.

ARTICLE INFORMATION

From the Social Genetic and Developmental Psychiatry Centre (KPG, JRIC, JE, SWC, KLP, GB, PM, PFO, CML), Institute of Psychiatry, Psychology and Neuroscience; National Institute for Health Research Biomedical Research Centre South London and Maudsley National Health Service Trust (JRIC, GB); and Department of Medical and Molecular Genetics (KBH, CML), King’s College London; Division of Psychiatry (GL), University College London, London; Division of Psychiatry (DHRB, AMM); and Centre for Cognitive Ageing and Cognitive Epidemiology (AMM), University of Edinburgh, Edinburgh; Medical Research Council Centre for Neurogenetic Psychiatry and Genomics (IJ), Cardiff University, Cardiff; Department of Psychological Medicine (LAJ), University of Worcester, Worcester; University of Liverpool (BM-M), Liverpool, United Kingdom; Genetics and Genomic Sciences (SWC, PFO), Icahn School of Medicine, Mount Sinai; Division of Epidemiology (MMW), New York State Psychiatric Institute; Department of Psychiatry (MMW), Columbia University College of Physicians and Surgeons, New York, New York; Department of Psychiatry and Behavioral Sciences (EBB), Emory University School of Medicine, Emory University, Atlanta, Georgia; Department of Psychiatry (ECD, JWS); Psychiatric and Neurodevelopmental Genomics Unit (ECM, ECD, JWS); and Analytic and Translational Genetics Unit (SR), Broad Institute, Cambridge, MA, USA (principal investigator, Samuel A. Weiss, Cambridge, MA, USA) and UK Biobank (https://www.ukbiobank.ac.uk/) to gain access to the supporting data.

ARTICLE INFORMATION

From the Social Genetic and Developmental Psychiatry Centre (KPG, JRIC, JE, SWC, KLP, GB, PM, PFO, CML), Institute of Psychiatry, Psychology and Neuroscience; National Institute for Health Research Biomedical Research Centre South London and Maudsley National Health Service Trust (JRIC, GB); and Department of Medical and Molecular Genetics (KBH, CML), King’s College London; Division of Psychiatry (GL), University College London, London; Division of Psychiatry (DHRB, AMM); and Centre for Cognitive Ageing and Cognitive Epidemiology (AMM), University of Edinburgh, Edinburgh; Medical Research Council Centre for Neurogenetic Psychiatry and Genomics (IJ), Cardiff University, Cardiff; Department of Psychological Medicine (LAJ), University of Worcester, Worcester; University of Liverpool (BM-M), Liverpool, United Kingdom; Genetics and Genomic Sciences (SWC, PFO), Icahn School of Medicine, Mount Sinai; Division of Epidemiology (MMW), New York State Psychiatric Institute; Department of Psychiatry (MMW), Columbia University College of Physicians and Surgeons, New York, New York; Department of Psychiatry and Behavioral Sciences (EBB), Emory University School of Medicine, Emory University, Atlanta, Georgia; Department of Psychiatry (ECD, JWS); Psychiatric and Neurodevelopmental Genomics Unit (ECM, ECD, JWS); and Analytic and Translational Genetics Unit (SR), Broad Institute, Cambridge, MA, USA (principal investigator, Samuel A. Weiss, Cambridge, MA, USA) and UK Biobank (https://www.ukbiobank.ac.uk/) to gain access to the supporting data.

ARTICLE INFORMATION

From the Social Genetic and Developmental Psychiatry Centre (KPG, JRIC, JE, SWC, KLP, GB, PM, PFO, CML), Institute of Psychiatry, Psychology and Neuroscience; National Institute for Health Research Biomedical Research Centre South London and Maudsley National Health Service Trust (JRIC, GB); and Department of Medical and Molecular Genetics (KBH, CML), King’s College London; Division of Psychiatry (GL), University College London, London; Division of Psychiatry (DHRB, AMM); and Centre for Cognitive Ageing and Cognitive Epidemiology (AMM), University of Edinburgh, Edinburgh; Medical Research Council Centre for Neurogenetic Psychiatry and Genomics (IJ), Cardiff University, Cardiff; Department of Psychological Medicine (LAJ), University of Worcester, Worcester; University of Liverpool (BM-M), Liverpool, United Kingdom; Genetics and Genomic Sciences (SWC, PFO), Icahn School of Medicine, Mount Sinai; Division of Epidemiology (MMW), New York State Psychiatric Institute; Department of Psychiatry (MMW), Columbia University College of Physicians and Surgeons, New York, New York; Department of Psychiatry and Behavioral Sciences (EBB), Emory University School of Medicine, Emory University, Atlanta, Georgia; Department of Psychiatry (ECD, JWS); Psychiatric and Neurodevelopmental Genomics Unit (ECM, ECD, JWS); and Analytic and Translational Genetics Unit (SR), Broad Institute, Cambridge, MA, USA (principal investigator, Samuel A. Weiss, Cambridge, MA, USA) and UK Biobank (https://www.ukbiobank.ac.uk/) to gain access to the supporting data.
Neurodevelopmental Genetics Unit (PNGU), Massachusetts General Hospital, Boston, Massachusetts; 42Stanley Center for Psychiatric Research, Broad Institute, Cambridge, Massachusetts; 41Department of Neuroscience and Mental Health, Cardinal University, Cardiff, United Kingdom; 43Bioinformatics, University of British Columbia, Vancouver, British Columbia, Canada; 44Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; 45Department of Mathematics, Massachusetts Institute of Technology, Cambridge, Massachusetts; 46Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, Germany; 47Department of Psychiatry (UPK), University of Basel, Basel, Switzerland; 48Department of Biomedicine, University of Basel, Basel, Switzerland; 49Centre for Human Genetics, University of Marburg, Marburg, Germany; 50Department of Psychiatry, Trinity College Dublin, Dublin, Ireland; 51Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland, USA; 52Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark; 53Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; 54Danish Headache Centre, Department of Neurology, Rigshospitalet, Glostrup, Denmark; 55Institute of Biological Psychiatry, Mental Health Center Sch. Hans, Mental Health Services Capital Region of Denmark, Copenhagen, Denmark; 56PSYCH, The Lundbeck Foundation Initiative for Psychiatric Research, Copenhagen, Denmark; 57Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia; 58Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine and Ernst Moritz Arndt University Greifswald, Greifswald, Germany; 59Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel F. Hoffmann-La Roche Ltd, Basel, Switzerland; 60Max Planck Institute of Psychiatry, Munich, Germany; 61MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, United Kingdom; 62Department of Psychiatric Medicine, University of Worcester, Worcester, United Kingdom; 63Division of Research, Kaiser Permanente Northern California, Oakland, California, USA; 64Department of Psychiatry and the Behavioral Sciences, University of Southern California, Los Angeles, California; 65Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts; 66Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts; 67Informatics Program, Boston Children’s Hospital, Boston, Massachusetts; 68Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom; 69Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Lausanne, Switzerland; 70Swiss Institute of Bioinformatics, Lausanne, Switzerland; 71Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom; 72Department of Mental Health, National Health Service, Glasgow, United Kingdom; 73Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany; 74Department of Statistics, University of Oxford, Oxford, United Kingdom; 75Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York, USA; 76School of Psychology and Counselling, Queensland University of Technology, Brisbane, Queensland, Australia; 77Child and Youth Mental Health Service, Children’s Health Queensland Hospital and Health Service, South Brisbane, Queensland, Australia; 78Child Health Research Centre, University of Queensland, Brisbane, Queensland, Australia; 79Estonian Genome Centre, University of Tartu, Tartu, Estonia; 80Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada; 81Department of Statistics, University of British Columbia, Vancouver, British Columbia, Canada; 82Department of Genetic Cardiovascular Research, Partner Site Greifswald, University Medicine, University Medicine Greifswald, Greifswald, Germany; 83Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany; 84Institute of Health and Biomedical Innovations, Queensland University of Technology, Brisbane, Queensland, Australia; 85Husum, Rey-kjavik, Iceland; 86Virginia Institute for Psychiatric & Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia; 87Clinical Genetics, Vrije Universiteit Universiteit Medical Center, Amsterdam, The Netherlands; 88Complex Trait Genetics, Vrije Universiteit Amsterdarn, The Netherlands; 89Department of Biochemistry and Molecular Biology II, Institute of Neurosciences, Biomedical Research Centre (CIBM), University of Granada, Granada, Spain; 90Department of Psychiatry, University of Groningen, University
REFERENCES

16. Wawrzczuk MA, Zavos H MS, Gregory AM, Eley TC (2014): The phenotypic and genetic structure of depression and anxiety disorder...


42. Li MX, Yeung JMY, Chen SS, Sham PC (2012): Evaluating the effective numbers of independent tests and significant p-value thresholds in commercial genotyping arrays and public imputation reference datasets. Hum Genet 131:747–756.

43. Purcell S, Chen SS, Sham PC (2003): Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19:149–150.


